Analysis Ocugen’s Insider Buy Sends a Quiet Signal as Clinical Catalysts Loom
The chief financial officer of Ocugen just put his own money on the line, purchasing 21,000 shares at $1.23 apiece days before the company reports second-quarter earnings on August 6....